IgorIvanovichRybkinMDPhD

Oncology • Detroit, MI

Thoracic Cancer

Medical Director

Join to view full profile

Dr. Rybkin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Rybkin's full profile

Already have an account?

Office
2800 West Grand Blvd.
Detroit, MI 48202
Phone+1 313-916-8758
Is this information wrong?

Clinical Expertise

Thoracic oncology, Clincial trials, Predictive genetic testing, Point-of-care assays, Predictive Assays, Oncology Care Model, Precision Medicine, Cancer care pathways development, Electronic Medical Records optimization, Squamous cell carcinoma of the nose, Branchiogenic carcinoma, Adenocarcinoma of the lung, Squamous cell carcinoma of the lung, Squamous cell carcinoma of the esophagus

Education & Training

University of Michigan Health SystemFellowship, Hematology and Medical Oncology, 2009 - 2012
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2006 - 2009
University of Texas Southwestern Medical CenterPhD, Genes and Development , 2003
Orenburg State Medical Academy Class of 1993, MD, Cum Laude

Certifications & Licensure

MI State Medical License 2009 - 2025

Awards, Honors, & Recognition

Top Doc List Hour Detroit Magazine, 2015-2020
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) Start of enrollment: 2015 Jun 11
Completed
Phase 2
A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer Start of enrollment: 2015 Mar 01
Completed
Phase 1, Phase 2
BIO 300 Non-Small Cell Lung Cancer Study Start of enrollment: 2015 Nov 01
Completed
Phase 1, Phase 2
Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2016 Feb 15
Completed
Phase 2
Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Start of enrollment: 2017 Aug 01
Completed
Phase 2, Phase 3
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients Start of enrollment: 2016 Jun 01
Active, not recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer Start of enrollment: 2016 Dec 20
Active, not recruiting
Phase 1, Phase 2
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer Start of enrollment: 2016 Nov 07
Terminated
Phase 2
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2017 Mar 04
Active, not recruiting
Phase 3
PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients Start of enrollment: 2017 May 24
Terminated
Phase 1
A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) Start of enrollment: 2017 May 02
Completed
Phase 3
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590) Start of enrollment: 2017 Jul 25
Completed
Phase 3
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC Start of enrollment: 2017 Aug 24
Active, not recruiting
Phase 3
Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC Start of enrollment: 2018 Mar 09
Enrolling by invitation
Early Phase 1
Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2018 Mar 19
Terminated
Phase 2
Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2018 Mar 22
Terminated
Phase 2
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) Start of enrollment: 2018 Apr 24
Active, not recruiting
Phase 3
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Start of enrollment: 2018 Sep 06
Active, not recruiting
Phase 1, Phase 2
Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions Start of enrollment: 2019 Mar 13
Terminated
Phase 2
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2019 Apr 16
Terminated
Phase 2
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors Start of enrollment: 2021 Jan 26
Recruiting
Phase 2
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2021 Dec 20
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

91 citations
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With AdvancedSolid Tumors (KRYSTAL-1).
Sai-Hong Ignatius Ou, Pasi A Jänne, Ticiana A Leal, Igor I Rybkin, Joshua K Sabari, Minal A Barve, Lyudmila Bazhenova, Melissa L Johnson, Karen L Velastegui, Cornelius...> ;Journal of Clinical Oncology. 2022 Aug 10
7 citations
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC.
D Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, Daniel Morgensztern, Rebecca Heist, Everett Vokes, Eric Angevin, David S Hong, Igor I Rybkin, Minal Barve, Todd M ...> ;JTO Clinical and Research Reports. 2022 Jan 1
2 citations
Pembrolizumab-Induced Vitiligo in Esophageal Squamous Cell Carcinoma Patient With Durable Complete Response
Matthew C. Wilkins, Igor I. Rybkin, Mohamed Elgamal> ;Cureus. 2021 Nov 19
208 citations
Acquired Resistance to KRASG12C Inhibition in Cancer
Mark M. Awad, Shengwu Liu, Igor I. Rybkin, Kathryn C. Arbour, Julien Dilly, Viola W. Zhu, Melissa Lynne Johnson, Rebecca S. Heist, Tejas Patil, Gregory J. Riely, Josep...> ;The New England Journal of Medicine. 2021 Jun 23
638 citations
The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients
Jill Hallin, Lars D. Engstrom, Lauren Hargis, Andrew Calinisan, Ruth Aranda, David Briere, Niranjan Sudhakar, Vickie Bowcut, Brian R. Baer, Joshua Ballard, Michael Bur...> ;Cancer Discovery. 2020 Jan 1
2 citations
Impact of Oral Chemotherapy Management Program on Capecitabine Toxicity Management.
Salin Nhean, Diana Kostoff, Jessica J Yang, Vishnuprabha Vogel, Igor I. Rybkin> ;JCO Oncology Practice. 2021 Apr 26
8 citations
American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020.
Stephen G. Chun, Charles B. Simone, Arya Amini, Indrin J. Chetty, Jessica S. Donington, Martin J. Edelman, Kristin Higgins, Larry L. Kestin, Benjamin Movsas, George Ro...> ;Journal of Thoracic Oncology. 2021 Jan 1
23 citations
Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)
David R. Spigel, Robert M. Jotte, John Nemunaitis, Merrill Kingman Shum, Jeffrey A. Schneider, Jerome H. Goldschmidt, Jennifer L. Eisenstein, David Berz, Lasika Senevi...> ;Journal of Thoracic Oncology. 2021 Feb 1
17 citations
American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer.
Arya Amini, Vivek Verma, Charles B. Simone, Indrin J. Chetty, J. Isabelle Choi, Stephen G. Chun, Jessica S. Donington, Martin J. Edelman, Kristin Higgins, Larry L. Kes...> ;International Journal of Radiation Oncology, Biology, Physics. 2020 Oct 1
10 citations
American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC
Kristin Higgins, Charles B. Simone, Arya Amini, Indrin J. Chetty, Jessica S. Donington, Martin J. Edelman, Stephen G. Chun, Larry L. Kestin, Benjamin Movsas, George Ro...> ;Journal of Thoracic Oncology. 2021 Jan 1
12 citations
Regulation of atrial natriuretic peptide secretion by a novel Ras-like protein
Igor I. Rybkin, Mi Sung Kim, Svetlana Bezprozvannaya, Xiaoxia Qi, James A. Richardson, Craig F. Plato, Joseph A. Hill, Rhonda S Bassel-Duby, Eric N. Olson> ;The Journal of Cell Biology. 2007 Nov 5
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng...> ;The New England journal of medicine. 2018-09-25
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennen...> ;The New England journal of medicine. 2018-04-16
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T, AL...> ;The New England journal of medicine. 2017-06-06
PS01.60: Ph Ib/II, Trial of INC280 ± Erlotinib vs Platinum + Pemetrexed in Adult pts with EGFR-Mutated, cMET amplified, EGFR TKI Resistant, Advanced NSCLC: Topic: Medi...
Igor I. Rybkin, Egbert F. Smit, Hans-Georg Kopp, Dong Wan Kim, Alexander I. Spira, Alfredo Berruti, Dae Ho Lee, Noemi Reguart, Mikhail Akimov, Karl Maria Schumacher, A...> ;Journal of Thoracic Oncology. 2016 Nov 1
78 citations
Calcineurin Is Necessary for the Maintenance but Not Embryonic Development of Slow Muscle Fibers
Misook Oh, Igor I. Rybkin, Victoria Copeland, Michael P. Czubryt, John M. Shelton, Eva van Rooij, James A. Richardson, Joseph A. Hill, Leon J. De Windt, Rhonda S Basse...> ;Molecular and Cellular Biology. 2005 Aug 1
549 citations
Transcriptional coactivator PGC-1α controls the energy state and contractile function of cardiac muscle
Zoltan Arany, Huamei He, Jiandie D. Lin, Kirsten Hoyer, Christoph Handschin, Okan Toka, Ferhaan Ahmad, Takashi Matsui, Sherry Chin, Pei Hsuan Wu, Igor I. Rybkin, John ...> ;Cell Metabolism. 2005 Apr 1
41 citations
Conditional expression of SV40 T-antigen in mouse cardiomyocytes facilitates an inducible switch from proliferation to differentiation.
Igor I. Rybkin, David W. Markham, Zhen Yan, Rhonda S Bassel-Duby, R. Sanders Williams, Eric N. Olson> ;The Journal of Biological Chemistry. 2003 May 2
20 citations
α1A Adrenergic Receptor Induces Eukaryotic Initiation Factor 4E-binding Protein 1 Phosphorylation via a Ca2+-dependent Pathway Independent of Phosphatidylinositol 3-ki...
Igor I. Rybkin, Michael E. Cross, E. Michael McReynolds, Richard Z. Lin, Lisa M. Ballou> ;The Journal of Biological Chemistry. 2000 Feb 25
133 citations
Effect of repeated stress on body weight and body composition of rats fed low- and high-fat diets
Ruth B. S. Harris, Jun Zhou, Bradley D Youngblood, Igor I. Rybkin, Gennady N. Smagin, Donna H. Ryan> ;The American Journal of Physiology. 1998 Dec 1
133 citations
Effect of restraint stress on food intake and body weight is determined by time of day
Igor I. Rybkin, You Zhou, Julia Volaufova, Gennady N. Smagin, Donna H. Ryan, Ruth B. S. Harris> ;The American Journal of Physiology. 1997 Nov 1
[A structural analysis of the myocardium in 2-month-old rats cultivated in vitro from the viewpoint of tissue homeostasis].
I I Rybkin> ;Neuroscience and Behavioral Physiology. 1995 Jan 1
Join now to see all